anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Therapy with LAMICTAL increases the risk of developing aseptic meningitis. Because of the potential for serious outcomes of untreated meningitis due to other causes, patients should also be evaluated for other causes of meningitis and treated as appropriate.

Postmarketing cases of aseptic meningitis have been reported in pediatric and adult patients taking LAMICTAL for various indications. Symptoms upon presentation have included headache, fever, nausea, vomiting, and nuchal rigidity. Rash, photophobia, myalgia, chills, altered consciousness, and somnolence were also noted in some cases. Symptoms have been reported to occur within 1 day to one and a half months following the initiation of treatment. In most cases, symptoms were reported to resolve after discontinuation of LAMICTAL. Re-exposure resulted in a rapid return of symptoms (from within 30 minutes to 1 day following re-initiation of treatment) that were frequently more severe. Some of the patients treated with LAMICTAL who developed aseptic meningitis had underlying diagnoses of systemic lupus erythematosus or other autoimmune diseases.

Cerebrospinal fluid (CSF) analyzed at the time of clinical presentation in reported cases was characterized by a mild-to-moderate pleocytosis, normal glucose levels, and mild-to-moderate increase in protein. CSF white blood cell count differentials showed a predominance of neutrophils in a majority of the cases, although a predominance of lymphocytes was reported in approximately one third of the cases. Some patients also had new onset of signs and symptoms of involvement of other organs (predominantly hepatic and renal involvement), which may suggest that in these cases the aseptic meningitis observed was part of a hypersensitivity reaction [see Warnings and Precautions (5.2)].
This scheme relates to cosmetics technical field. More particularly, the scheme relates to toner with anti-wrinkle, moisturizing and whitening effects. The toner comprises, by weight, 3-5% of alantolactone, 1-2% of caragana microphylla leaf extract and 1-3% of pine needle extract. The toner disclosed by the invention can realize a good whitening effect by specifically inhibiting the mechanism that tyrosinase blocks melanin generation. Meanwhile, the toner has a good antioxidant repair function, and the whitening effect of the toner is coordinately enhanced through the mutual promotion effect among the natural extracts in the components, so that the product has the effects of whitening, moisturizing, resisting aging, resisting wrinkles, fading color spots and the like. Meanwhile, the skin quality can be rapidly improved, the skin elasticity can be improved, wrinkles can be smoothed, and the like.
The intervention to be implemented in the intervention county involves enhancing its existing SSP model with a KyOSK. The intervention county SSP operates identically to the comparison county. As in the comparison county, a card reader will be installed in the intervention county SSP at the beginning of the study to provide objective data on visits and supply access. The KyOSK will resemble a vending machine. The KyOSK will include harm reduction, wound care, hygiene, and other supplies; offer overdose education and other content; a sharps container with a device to obtain data on syringe disposal; and an innovative call-back feature for care navigation by recovery coaches. While the KyOSK is operating, the intervention county will operate its traditional SSP 40 hours/week.
The invention relates to a maca health-care wine and a preparation method thereof. The maca health-care wine is prepared from the following components in parts by mass: 2-10 parts of maca functional extract, 0.1-5 parts of kudzu root functional extract and 85-97.9 parts of wine. The preparation method comprises the following steps: by using maca and kudzu root as raw materials, preparing maca andkudzu root functional extracts by a normal-temperature ultrasonic extraction technique, proportionally adding the extracts into wine in the form of solid dry powder or concentrated solution, filtering, sterilizing, and filling. The method is suitable for preparing maca health-care wines from white wine, yellow wine, wine, beer and fruit wine, and has the advantages of simple production technique and quantitative and controllable effective components; and the maca health-care wine not only performs the multiple health-care functions of maca, but also reduces the injury of alcohol on the human body by using the effective components in kudzu root. The maca health-care wine provided by the invention has the effects of relieving fatigue, resisting pressure, resisting radiation, improving the immunity, enhancing the sexual function, adjusting the incretion, improving the sleep, lowering the blood fat, postponing senility, protecting the liver and the like. The maca and kudzu root functionalextracts enhance the bioavailability of the respective functional components, and therefore, the maca health-care wine has wide application prospects in the aspect of preventing and improving sub-health.
This study included patients with newly diagnosed AL amyloidosis who were treated with a BD regimen in Jinling hospital. The AL amyloidosis diagnosis was confirmed by renal biopsy, and the assessment of organ involvement were based on consensus criteria. The clinical and laboratory data were collected at the beginning of each cycle and every 3 months thereafter. The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The investigators evaluated the efficacy and safety of BD as the first-line treatment of patients with AL amyloidosis.
Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control. Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
The present invention relates to a medicine containing galangin, and a preparation method thereof, which relates to the field of medicine. The medicine is used for resisting viruses and tumors, and contains galangin total flavonoids obtained by extracting and separating rhizomes of the galanga of zingiberaceous plants, wherein the content of total flavonoids is 50 to 99.8% and the content of the galangin is 30 to 80% measured by weight of dried products. The method for preparing galangin total flavonoids comprises the steps of abstraction from galanga plants, extraction, back extraction, total flavonoids precipitation and purification, and then the galangin total flavonoids is used for preparing injections or oral preparations. The medicine has the advantages of simple preparation process, easy acquirement of raw materials, convenient separation and purification of the product, high purity of the obtained product and low production cost, and is convenient in scale production. The medicine containing galangin total flavonoids has the advantage of definite medicine efficacy, and the preparation of the medicine is convenient for clinical application. The medicine containing the galangin total flavonoids not only has antivirus and anti-tumor effect, but also is developed into medicines used for chemical protection, antioxidation, antibiosis and antiphlogosis.
Long term in vivo studies have not been performed to evaluate the carcinogenic potential of cefprozil.

Cefprozil was not found to be mutagenic in either the Ames Salmonella or E. coli WP2 urvA reversion assays or the Chinese hamster ovary cell HGPRT forward gene mutation assay and it did not induce chromosomal abnormalities in Chinese hamster ovary cells or unscheduled DNA synthesis in rat hepatocytes in vitro. Chromosomal aberrations were not observed in bone marrow cells from rats dosed orally with over 30 times the highest recommended human dose based upon mg/m2.

Impairment of fertility was not observed in male or female rats given oral doses of cefprozil up to 18.5 times the highest recommended human dose based upon mg/m2.

Pregnancy: Teratogenic Effects. Pregnancy Category B

Reproduction studies have been performed in rabbits, mice, and rats using oral doses of cefprozil of 0.8, 8.5, and 18.5 times the maximum daily human dose (1000 mg) based upon mg/m2, and have revealed no harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Data will be collected for participants initiating therapy with either methotrexate or an anti-tumor necrosis factor (TNF) from united states (US) claims databases: optum de-identified clinformatics data mart database and IBM marketscan medicare supplemental database (MDCR). Data collection period: 01-Jan-2000 through 31-Jul2019.
Patients should be informed of the possibility of severe liver disease or skin reactions associated with VIRAMUNE that may result in death. Patients developing signs or symptoms of liver disease or severe skin reactions should be instructed to discontinue VIRAMUNE and seek medical attention immediately, including performance of laboratory monitoring. Symptoms of liver disease include fatigue, malaise, anorexia, nausea, jaundice, acholic stools, liver tenderness or hepatomegaly. Symptoms of severe skin or hypersensitivity reactions include rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema and/or hepatitis.

Intensive clinical and laboratory monitoring, including liver enzymes, is essential during the first 18 weeks of therapy with VIRAMUNE to detect potentially life-threatening hepatotoxicity and skin reactions. However, liver disease can occur after this period; therefore, monitoring should continue at frequent intervals throughout VIRAMUNE treatment. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of hepatic events and skin reactions. Patients with signs and symptoms of hepatitis should discontinue VIRAMUNE and seek medical evaluation immediately. If VIRAMUNE is discontinued due to hepatotoxicity, do not restart it. Patients, particularly women, with increased CD4+ cell count at initiation of VIRAMUNE therapy (>250 cells/mm3 in women and >400 cells/mm3 in men) are at substantially higher risk for development of symptomatic hepatic events, often associated with rash. Patients should be advised that co-infection with hepatitis B or C and/or increased transaminases at the start of therapy with VIRAMUNE are associated with a greater risk of later symptomatic events (6 weeks or more after starting VIRAMUNE) and asymptomatic increases in AST or ALT [see Boxed Warning and Warnings and Precautions (5.1)].

The majority of rashes associated with VIRAMUNE occur within the first 6 weeks of initiation of therapy. Patients should be instructed that if any rash occurs during the two-week lead-in period, the VIRAMUNE dose should not be escalated until the rash resolves. The total duration of the once-daily lead-in dosing period should not exceed 28 days, at which point an alternative regimen may need to be started. Any patient experiencing a rash should have their liver enzymes (AST, ALT) evaluated immediately. Patients with severe rash or hypersensitivity reactions should discontinue VIRAMUNE immediately and consult a physician. VIRAMUNE should not be restarted following severe skin rash or hypersensitivity reaction. Women tend to be at higher risk for development of VIRAMUNE-associated rash [see Boxed Warning and Warnings and Precautions (5.2)].
PURPOSE:To obtain a percutaneously absorbable type pharmaceutical of diltiazem hydrochloride readily absorbable from the skin. CONSTITUTION:A percutaneously absorbable type pharmaceutical composed of diltazem hydrochloride and cyclopentadecanone (CPD). Since the CPD is used as a percutaneous absorbefacient, the diltiazem hydrochloride can efficiently be absorbed from the skin. The aforementioned percutaneous absorbable type pharmaceutical is capable of sustainedly and efficiently absorbing the diltiazem hydrochloride. Thereby, the pharmaceutical is useful for preventing and treating fit of angina pectoris. The bioavailability of the diltiazem hydrochloride can be improved to reduce side effects on digestive tracts.
Disclosed techniques relate to identifying subjects in digital images. In various embodiments, digital image(s) that depict a subject in an area may be acquired. Portion(s) of the digital image(s) that depict a face of the subject may be detected as detected face image(s). Features of each of the detected face image(s) may be compared with features of each of a set of subject reference templates associated with a given subject in a subject reference database. Based on the comparing, a subject reference template may be selected from the set of subject reference templates associated with the given subject. Similarity measure(s) may then be determined between a given detected face image of the detected face image(s) and the selected subject reference template. An identity of the subject may be determined based on the similarity measure(s).
BACKGROUND: Hypertrophic scars, an abnormal wound-healing response to burn injuries, are characterized by massive fibroblast proliferation and excessive deposition of extracellular matrix and collagen. 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) is a promising therapy for hypertrophic scar, details of the mechanisms remain to be elucidated. In this study, we aimed to investigate the molecular mechanisms involved in ALA-PDT against hypertrophic scar fibroblasts.
METHODS: The morphologies of hypertrophic scar fibroblasts (HSFs) treated with ALA-PDT were observed under a light microscopy. The viability of HSFs was detected using the CCK-8 assay. HSFs-populated collagen gel contraction assays were conducted to examine the fibroblast contractility and the cytotoxicity of HSFs in 3D collagen tissues were observed using confocal microscopy. The effect of ALA-PDT on TGF-β1/Smad2/3/4 signaling pathway activation and effector gene expression were verified by immunoprecipitation, western blot and real-time quantitative PCR analysis.
RESULTS: We observed significant changes in cell morphology after ALA-PDT treatment of HSFs. As ALA concentration and light dose increased, the viability of HSFs significantly decreased. ALA-PDT can significantly alleviate the contractile capacity and promote the death of HSFs induced by TGF-β1 treatment in a three-dimensional collagen culture model. TGF-β1 treatment of HSFs can significantly induce phosphorylation of Smad2/3 (p-Smad2/3) in whole cells, as well as p-Smad2/3 and Smad4 proteins into the nucleus and increase the mRNA levels of collagen 1/3 and α-SMA. ALA-PDT hampers the TGF-β1-Smad2/3/4 signaling pathway activation by inducing K48-linked ubiquitination and degradation of Smad4.
CONCLUSIONS: Our results provide evidence that ALA-PDT can inhibit fibroblast contraction and promote cell death by inhibiting the activation of the TGF-β1 signaling pathway that mediates hypertrophic scar formation, which may be the basis for the efficacy of ALA-PDT in the treatment of hypertrophic scars.
<P>PROBLEM TO BE SOLVED: To provide a powder-containing water-in-oil type emulsion cosmetic having good extensibility on the skin, excellent in emollient properties and moisture retention and duration of their effects and having no stickiness and oiliness.  <P>SOLUTION: The powder-containing water-in-oil type emulsion cosmetic contains an ester of a branched fatty acid with a branched alcohol. The ester is isostearyl pivalate. The cosmetic contains 0.1-30 mass% isostearyl pivalate based on the total amount of a composition. The cosmetic contains one or more species of titanium oxide, zinc oxide and cerium oxide.  <P>COPYRIGHT: (C)2004,JPO
Scleral contact lenses are rigid gas permeable lenses designed to rest on the sclera while vaulting over the cornea with a fluid reservoir. The use of scleral contact lenses has become the current standard of practice as a nonsurgical management of corneal ectasia and ocular surface diseases. Cases have been recently presented of scleral lens wearers exhibiting adverse corneal findings and conjunctival injection from lens wear. These findings are likely associated with the mechanical and hypoxic effects due to poor fitting characteristics at the limbal area. Tear film analysis detecting changes in the levels of proteinases and cytokines have helped researchers gain a better understanding of the pathophysiology of complications in soft contact lenses wearers, dry eye, and keratoconus. Ultimately, this study will provide insights in relating scleral lens fitting characteristics and corneal and limbal physiological responses.
Radiation therapy for prostate cancer leads to inappropriate radiation dose to the rectum wall leading rectum adverse effects in long term for some patients. A resorbable spaces between prostate and rectum could decrease the incidence of these side effect. In this trial, men with prostate cancer with intention to curative treatment by low-dose brachytherapy will be recruited. The subjects will be randomized to receive either diluted or non-diluted DuraSeal product as a spacer between prostate and rectum. Diluted or non-diluted DuraSeal will be applied between rectum and prostate at the end of the brachytherapy seed implantation procedure. After the implantation of the brachytherapy seeds, a needle is placed between rectum and prostate through perineal skin under transrectal ultrasound guidance. The proper position of the needle is confirmed by the injection of 10-15 ml sterile saline solution. After that, DuraSeal components are diluted in 1:1 with sterile saline and 6-10 ml of this diluted product will be injected using DuraSeal applicator. If the subject is randomized to receive non-diluted DuraSeal, the procedure will be identical with the exception the DuraSeal components will not be diluted. The resolution of the spacer will be followed by repeated plain computer tomography (CT) of pelvis performed a day before operation, a day after the operation, and 4, 8 and 12 weeks after the operation. In addition, magnetic resonance imaging of pelvis performed 12 weeks after the operation. The space created between prostate and rectum will be documented by plain CT and magnetic resonance imaging. Rectum radiation dose will be calculated based on these scans. Time to DuraSeal resolution will be evaluated from the scans. Possible side effects will be collected by subject interviews during follow-up visits at 4, 8 and 12 weeks after the operation.
Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
Biotic and abiotic stresses have emerged as major constraints to agricultural production, causing irreversible adverse impacts on agricultural production systems and thus posing a threat to food security. In this study, a new strain of Bacillus subtilis DNYB-S1 was isolated from soil contaminated with Fusarium wilt. It was found that artificially synthetic flora (YJ-1) [Enterobacter sp. DNB-S2 and Rhodococcus pyridinovorans DNHP-S2, DNYB-S1] could effectively mitigate both biotic (Fusarium wilt) and abiotic (phthalates) sources of stresses, with the inhibition rate of YJ-1 resistant to wilt being 71.25% and synergistic degradation of 500 mg/L PAEs was 91.23%. The adaptive difference of YJ-1 was 0.59 and the ecological niche overlap value was -0.05 as determined by Lotka-Volterra modeling. These results indicate that YJ-1 has good ecological stability. The major degradation intermediates included 2-ethylhexyl benzoate (EHBA), phthalic acid (PA), diisobutyl phthalate (DIBP), and butyl benzoate, suggesting that YJ-1 can provide a more efficient pathway for PAEs degradation. In addition, there was metabolic mutualism among the strains that will selectively utilize the provided carbon source (some metabolites of PAEs) for growth. The pot experiment showed that YJ-1 with cucumber reduced the incidence of cucumber wilt by 45.31%. YJ-1 could reduce the concentration of PAEs (DBP: DEHP = 1:1) in soil species from 30 mg/kg to 4.26 mg/kg within 35 d, with a degradation efficiency of 85.81%. Meanwhile, the concentration of PAEs in cucumber was reduced to 0.01 mg/kg, indicating that YJ-1 is directly involved in the degradation of soil PAEs and the enhancement of plant immunity. In conclusion, this study provides a new perspective for the development of customized microbiomes for phytoremediation under combined biotic-abiotic stresses in agricultural production processes.
The invention relates to the medicine field, and concretely relates to a yacon protein polypeptide. The yacon protein polypeptide can prevent or treat atherosclerosis. The polypeptide sequence is ERDEFEKYDKVHNIRPKMVS. The preparation method for the polypeptide comprises steps: firstly, dried yacon is ground into powder and is sieved through a 50-100-mesh sieve; secondly, alkaline water is added and the powder is dissolved; thirdly, centrifugation with a speed of 5000-7000rpm is carried out for 20-30min, and precipitates are taken; fourthly, the precipitates are dissolved, and the pH value is adjusted to 1-2; fifthly, non-restrictive hydrolysis proteases are added and enzymatic hydrolysis is carried out; sixthly, protein separation is carried out; seventhly, semi-prepared RP-HPLC separation and purifying are carried out; eighthly, freeze-drying is carried out. The non-restrictive hydrolysis protease enzymatic hydrolysis employs pepsin, trypsin, papain and papain for enzymatic hydrolysis. The protein separation employs macroporous resins and glucan gel. Provided are applications of the polypeptide in treating atherosclerosis. The yacon protein polypeptide is a polypeptide extracted from yacon protein, is safe, and can prevent or treat atherosclerosis effectively.
<P>PROBLEM TO BE SOLVED: To provide polynucleotide-based cytomegalovirus vaccines.  <P>SOLUTION: There are provided plasmids operably encoding HCMV antigens, in which in plasmids the naturally-occurring coding regions for the HCMV antigens are modified for improved translation in human or other mammalian cells through codon optimization. The plasmids as useful HCMV antigens are pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. The plasmids deleted in e.g. the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB in the coding regions are provided. The pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators are provided.  <P>COPYRIGHT: (C)2011,JPO&INPIT